New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
08:47 EDTTEVA, BBRY, DISH, MSFT, ORCL, UBS, BRCM, DRI, GE, INTC, LVS, PFE, HPQ, FOn the Fly: Periodicals Wrap
WSJ: Las Vegas Sands' (LVS) Adelson: 'I'd spend $10B in Japan'... Starboard wants Red Lobster spinoff vote by Darden (DRI) shareholders...HP's (HPQ) Whitman: 'Hardware increasingly being pivoted to software'...Chip makers (INTC, BRCM) race to offer faster mobile networks...Pfizer (PFE) to again ship thyroid drug Levoxyl following recall...REUTERS: GE (GE) to increase energy research $10B by 2020...BLOOMBERG: Ford (F) to dump Microsoft (MSFT) for BlackBerry (BBRY) in next-generation Sync...UBS (UBS) wants immunity from U.S., EU in fx investigations...LightSquared says Dish's (DISH) Ergen can agree to plan or risk $1B...Teva (TEVA) advances amidst takeover speculation...OTHER NEWS: Oracle (ORCL) close to buying BlueKai for about $400M, Business Insider reports.
News For LVS;DRI;HPQ;INTC;BRCM;PFE;GE;F;MSFT;BBRY;UBS;DISH;TEVA;ORCL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | all recent news | >>
April 22, 2015
09:56 EDTTEVAMylan planning firmer offer for Perrigo, CNBC's Faber reports
Mylan (MYL) is planning to announce a firmer takeover offer for Perrigo (PRGO) that will include financing commitments and ticking fees, CNBC's David Faber reports, citing people familiar with the matter. It is unclear if the offer will include a higher buyout price of $205 per share, Faber added.
09:44 EDTTEVASources: Mylan planning new offer for Perrigo, CNBC's Faber says
Subscribe for More Information
09:37 EDTINTCAltera quarterly results 'may not be great,' CNBC's Faber reports
There is talk that Altera's (ALTR) earnings report "may not be great" when the chip company reports Q1 results on Thursday, April 23, CNBC's David Faber reports. Investors assume Altera will report a strong quarter after turning down Intel's takeover attempt, but that may not be the case, according to Faber. Shares of the chip maker are down 35c to $42.89 in early trading. Piper Jaffray this morning downgraded the stock to Neutral.
09:32 EDTINTCASML large EUV tool order likely from Intel, says Summit Research
Subscribe for More Information
09:22 EDTBRCMOn The Fly: Pre-market Movers
UP AFTER EARNINGS: CalAmp (CAMP), up 12.7%... Angie's List (ANGI), up 17.4%... Broadcom (BRCM), up 6.3%... Owens Corning (OC), up 3.8%... Yum! Brands (YUM), up 3.3%... Dolby Laboratories (DLB), up 3.6%... Infinera (INFN), up 2.4%... AutoNation (AN), up 2.5%... Amgen (AMGN), up 3.1%... Coca-Cola (KO), up 2%. ALSO HIGHER: Procera Networks (PKT) up 10.4% after being acquired by Francisco Partners in deal valued at $240M... Organovo (ONVO), up 19.2% after entering into a collaboration agreement with Merck Sharp and Dohme... Vical (VICL), up 5.8% after being awarded $4M contract to manufacture HIV vaccines for clinical evaluation... CTI BioPharma (CTIC), up 4.9% after announcing that Phase 3 pacritinib data will be highlighted in a late-breaking oral presentation at ASCO meeting. DOWN AFTER EARNINGS: Chipotle Mexican Grill (CMG), down 5.2%... iRobot (IRBT), down 3.6%... Cree (CREE), down 3.5%... United Rentals (URI), down 4%... Super Micro Computer (SMC), down 2.3%... Thermo Fisher (TMO), down 2.6%. ALSO LOWER: Natural Resource Partners (NRP), down 14% after reducing quarterly distribution 75% to 9c per unit... Trinity Industries (TRN), down 3.5% following a Bloomberg report that the Justice Department has initiated a criminal investigation into Trinity guardrails.
09:08 EDTTEVATeva price target raised to $75 from $64 at Argus
Subscribe for More Information
09:02 EDTGEAdvanced Power selects GE for 7F.05 gas turbines
Subscribe for More Information
08:43 EDTTEVAHostile bids carry low success rates, says Leerink
Subscribe for More Information
08:42 EDTTEVAMylan likely to seek higher offer from Teva, says Bernstein
after Teva (TEVA) offered to buy Mylan (MYL) for $82 per share, Bernstein expects Mylan to seek an offer closer to $90. The firm also expects Mylan to seek shared management and perhaps some protection for its employees. Bernstein expects Teva to attempt to convince Mylan shareholders of the merits of its offer and Mylan to attempt to convince Perrigo (PRGO) shareholders of the merits of its offer and its own shareholders of the risks associated with the Teva deal. Bernstein keeps Outperform ratings on Teva and Mylan.
08:31 EDTTEVATeva files for Hart Scott Rodino notification regarding proposed Mylan purchase
Teva Pharmaceutical Industries (TEVA) announced that it has filed for premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission regarding its proposed acquisition of Mylan N.V. (MYL). As announced on April 21, 2015, Teva proposed to acquire Mylan for $82.00 per Mylan share, with the consideration to be comprised of approximately 50% cash and 50% stock. Teva’s proposal for Mylan implies a total equity value of approximately $43 billion and an enterprise value of approximately $50 billion. The Teva Board and management team are committed to consummating a transaction as soon as possible. The acquisition proposal would provide Teva stockholders with very attractive strategic and financial benefits and Mylan stockholders with a substantial premium and immediate value for their shares, as well as the opportunity to participate in the significant upside potential of the combined company – one that would transform the global generics space and leverage it to hold a unique leadership position in the pharmaceutical industry. Teva has carefully studied the regulatory aspects of a combination of Teva and Mylan, in conjunction with its advisors. Teva is confident that it would be able to structure a transaction that would not contain material impediments to closing and that it can determine and promptly implement divestitures, as necessary, to gain regulatory clearances. Teva intends to work cooperatively with antitrust authorities and expects that the proposed transaction can be completed by year-end 2015. Teva’s proposal provides Mylan stockholders with a more attractive alternative to Mylan’s proposed acquisition of Perrigo Company plc (PRGO), as announced on April 8, 2015, as well as to Mylan on a standalone basis. Teva’s proposal would provide Mylan stockholders with consideration representing a 37.7% premium to the stock price of Mylan on April 7, 2015, which is the last day of trading prior to Mylan’s press release regarding its unsolicited proposal for Perrigo, and a 48.3% premium to the unaffected stock price of Mylan on March 10, 2015, which is the last day of trading prior to widespread speculation of a transaction between Teva and Mylan. Barclays and Greenhill & Co. are serving as financial advisors to Teva. Kirkland & Ellis LLP and Tulchinsky Stern Marciano Cohen Levitski & Co are serving as legal counsel to Teva, with De Brauw Blackstone Westbroek N.V. and Loyens & Loeff N.V. acting as legal advisors in the Netherlands.
08:16 EDTMSFTSeveral companies to benefit from hybrid cloud growth, says Pacific Crest
Subscribe for More Information
08:14 EDTBRCMBroadcom remains a top semi pick after Q1 results at JPMorgan
Subscribe for More Information
07:27 EDTTEVAPiper sees more sense in Teva buying Perrigo than Mylan
Piper Jaffray says that while a potential acquisition of Mylan (MYL) by Teva (TEVA) would bring major cost synergies and meaningful earnings accretion, it would not significantly improve the limited visibility on long-term top-line and earnings growth for Teva. Piper sees more strategic sense in Teva acquiring Perrigo (PRGO). Such a deal would drive multiple expansion for Teva since Perrigo's Consumer Health and Nutritionals businesses can offer a "much higher level of visibility on robust long-term earnings growth" than what Mylan can offer Teva, Piper tells investors today. The firm reiterates a Neutral rating on shares of Teva.
07:14 EDTTEVATeva Mylan deal more likely to get done than Mylan Perrigo deal,says Wells Fargo
Subscribe for More Information
07:11 EDTBRCMBroadcom price target raised to $59 from $53 at Brean Capital
Brean Capital raised its price target on Broadcom to $59 from $53 following its beat and raise Q1 results. The firm cited strength in its infrastructure and networking segments, tight cost management, and raised guidance. Brean Capital reiterated its Buy rating on Broadcom shares.
06:31 EDTTEVAMylan likely to improve offer for Perrigo, says Citigroup
Citigroup believes Mylan's (MYL) board will likely reject Teva's (TEVA) initial takeover offer of $82 per share and present an improved proposal to acquire Perrigo (PRGO). Citi continues see a potential Teva-Mylan combination as more value accretive for Mylan shareholders than a potential Mylan-Perrigo combination. It keeps a Neutral rating on Mylan.
06:30 EDTTEVAMylan shareholders urge board to consider Teva offer, Reuters reports
Subscribe for More Information
06:21 EDTGEGeneral Electric to look to sell Czech banking unit, Reuters says
General Electric will divest its Czech banking subsidiary, believed to be worth more than $787M, within two years, a newspaper quoted the bank's CEO as saying, according to Reuters. Reference Link
05:59 EDTGEStocks with implied volatility below IV index mean; ALU GE
Subscribe for More Information
05:43 EDTINTCAltera downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Ruben Roy downgraded Altera (ALTR) to Neutral from Overweight saying takeover speculation has driven the valuation above a fundamentals based fair value. He believes an acquisition by Intel (INTC) makes sense, but at a reasonable valuation. The analyst thinks a higher premium than $54 per share is unlikely. Piper keeps a $42 price target for shares of Altera. Roy still views the longer-term prospects for the programmable logic device companies favorably and thinks Altera is better positioned near-term versus Xilinx (XLNX). Shares of Altera closed yesterday up 8c to $43.24.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use